Moderna price target raised to $30 from $25 at RBC Capital

RBC Capital analyst Luca Issi raised the firm’s price target on Moderna (MRNA) to $30 from $25 and keeps a Sector Perform rating on the shares. The company’s Q4 report was relatively incremental as top-line was pre-reported in early-January, the analyst tells investors in a research note. Despite all the progress, the firm remains on the sidelines awaiting further clarity on top-line re-inflection, RBC added.